Strides Pharma Science Ltd is Rated Hold

Current Rating and Its Significance

The 'Hold' rating assigned to Strides Pharma Science Ltd indicates a neutral stance for investors. It suggests that while the stock may not offer significant upside potential in the near term, it also does not warrant a sell recommendation. Investors are advised to maintain their existing positions and monitor the company’s performance closely. This rating reflects a balanced view considering multiple factors including quality, valuation, financial trends, and technical indicators.

Quality Assessment

As of 29 December 2025, Strides Pharma Science Ltd exhibits a below-average quality grade. The company’s long-term fundamental strength remains weak, with an average Return on Capital Employed (ROCE) of 7.27%. Over the past five years, net sales have grown at an annual rate of 9.87%, while operating profit has increased by 12.79% annually. Although these growth rates indicate some expansion, they fall short of robust industry benchmarks. Additionally, the company’s debt servicing ability is a concern, with a high Debt to EBITDA ratio of 6.58 times, signalling elevated leverage and potential financial risk.

Valuation Perspective

Currently, the valuation grade for Strides Pharma Science Ltd is attractive. The company’s ROCE of 15.6% combined with an Enterprise Value to Capital Employed ratio of 2.3 suggests that the stock is trading at a discount relative to its peers’ historical valuations. This valuation appeal is further supported by the stock’s performance over the past year, which has delivered a 34.26% return as of 29 December 2025. Despite this, it is important to note that profits have declined by 14.7% during the same period, indicating some underlying operational challenges that investors should consider.

Financial Trend Analysis

The financial trend for Strides Pharma Science Ltd is positive as of the current date. The company has reported positive results for nine consecutive quarters, demonstrating operational resilience. Quarterly operating profit to interest coverage stands at a healthy 5.02 times, indicating adequate earnings to cover interest expenses. Profit Before Tax excluding other income reached Rs 134.75 crores, growing at an impressive rate of 118.50%. Quarterly PBDIT peaked at Rs 231.56 crores, underscoring improving profitability. However, the company’s high promoter share pledge of 44.13% remains a risk factor, as it could exert downward pressure on the stock price during market downturns.

Technical Outlook

From a technical standpoint, Strides Pharma Science Ltd is currently rated bullish. The stock has shown consistent returns over the last three years, outperforming the BSE500 index in each of those annual periods. Recent price movements include a modest decline of 0.12% on the last trading day, a 4.54% drop over the past week, but a 3.52% gain in the last month and an 11.62% rise over three months. The year-to-date return stands at a robust 38.28%, reflecting positive investor sentiment and momentum. These technical signals support the 'Hold' rating by suggesting that while the stock is not in a strong buy zone, it maintains upward momentum worthy of investor attention.

Summary for Investors

In summary, Strides Pharma Science Ltd’s 'Hold' rating as of 29 September 2025 reflects a balanced view of the company’s current position as of 29 December 2025. Investors should weigh the attractive valuation and positive financial trends against the below-average quality metrics and elevated leverage risks. The stock’s consistent returns and bullish technical indicators provide some confidence, but the high promoter pledge and profit decline warrant caution. Maintaining existing holdings while monitoring quarterly results and market conditions appears prudent at this stage.

Company Profile and Market Context

Strides Pharma Science Ltd is a small-cap company operating within the Pharmaceuticals & Biotechnology sector. The company’s market capitalisation and sector dynamics influence its valuation and investor perception. The Mojo Score currently stands at 57.0, reflecting a moderate overall assessment, with the Mojo Grade assigned as 'Hold'. This score improved by 14 points from the previous 43, indicating some positive developments in the company’s outlook since the last rating update on 29 September 2025.

Stock Performance Overview

As of 29 December 2025, the stock has delivered a 34.26% return over the past year, outperforming many peers and the broader market indices. The year-to-date return is even stronger at 38.28%, signalling solid investor confidence. Shorter-term performance shows some volatility, with a slight dip over the past week but gains over the last month and quarter. This mixed performance highlights the importance of a cautious approach, consistent with the 'Hold' rating.

Risks and Considerations

Investors should be mindful of the company’s high debt levels and the significant proportion of promoter shares pledged. These factors could increase vulnerability to market fluctuations and impact stock price stability. Additionally, the decline in profits despite strong returns suggests operational challenges that require monitoring. The below-average quality grade further emphasises the need for careful evaluation before increasing exposure.

Conclusion

Strides Pharma Science Ltd’s current 'Hold' rating by MarketsMOJO, last updated on 29 September 2025, reflects a nuanced view of the company’s prospects as of 29 December 2025. While valuation and technical indicators offer some encouragement, fundamental weaknesses and financial risks temper enthusiasm. Investors are advised to maintain their positions and stay informed on quarterly results and sector developments to make timely decisions.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year (MRP = Rs. 34,999) Start Today